| Vol. 21.22 – 22 June, 2020 |
| |
|
|
| Intravenous delivery of immunity- and matrix-regulatory cells, derived from human embryonic stem cells, inhibited both pulmonary inflammation and fibrosis in mouse models of lung injury, and significantly improved the survival rate of the recipient mice in a dose-dependent manner, likely through paracrine regulatory mechanisms. [Cell Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists investigated adding haplo-identical CD34+ cells to double unit cord blood (CB) grafts to facilitate early haplo-identical donor-derived neutrophil recovery prior to CB engraftment. [Leukemia] |
|
|
|
| Investigators demonstrated that the adoptive transfer of gingiva derived mesenchymal stem cells homes to and maintains in the kidney and had a robust therapeutic effect in a spontaneous lupus nephritis model. [Journal of Autoimmunity] |
|
|
|
| Scientists compared the osteogenic differentiation and bone defect repairment characteristics of bone marrow mesenchymal stem cells sheets derived from alveolar bone and iliac bone in vitro and in vivo. [Journal of Tissue Engineering] |
|
|
|
| The effects of human amniotic fluid stem cell transplantation on bladder function and molecular changes in spinal cord-injured rats were investigated. [Scientific Reports] |
|
|
|
| Scientists enhanced the effect of cardiosphere-derived cells with APOSEC preconditioning (apoCDC), and investigated the reparative effect in a translational pig model of reperfused MI. [Molecular Therapy-Methods & Clinical Development] |
|
|
|
| The authors investigated whether donor natural killer cells and interleukin-2 gene modification exerted anti-relapse effects on allogeneic hematopoietic stem-cell transplantation after establishing a mouse model of acute leukemia. [Cancer Biomarkers] |
|
|
|
|
| The authors summarize the current preclinical and clinical studies performed to investigate the regenerative potential of Wharton’s jelly‐derived mesenchymal stem cells in neural, myocardial, skin, liver, kidney, cartilage, bone, muscle, and other tissue injuries. [Journal of Cellular Physiology] |
|
|
|
|
| UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health (NIH) to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV. [University of California, Los Angeles] |
|
|
|
| Ovid Therapeutics Inc. announced a strategic research collaboration with Columbia University Irving Medical Center researchers to advance genetic based therapies for a range of rare neurological conditions, complementary to Ovid’s current pipeline. [Ovid Therapeutics Inc.] |
|
|
|
| City of Hope have signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc. Scopus will further develop and plans to commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy. [City of Hope] |
|
|
|
|
| 2020-06-23 – 2020-06-27 Virtual |
|
|
|
|
|
| Gilbert Family Foundation – Detroit, Michigan, United States |
|
|
|
| Terasaki Institute for Biomedical Innovation – Los Angeles, California, United States |
|
|
|
| Guangzhou Regenerative Medicine and Health Guangdong Laboratory – Guangzhou, China |
|
|
|
| University of Washington – Seattle, Washington, United States |
|
|
|
| Vrije Universiteit Brussels – Brussels, Belgium |
|
|
|
| Empyrean Therapeutics Ltd – Cambridge, United Kingdom |
|
|
|
| University of Chicago – Chicago, Ilinois, United States |
|
|
|
| Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
| Wake Forest School of Medicine – Winston Salem, North Carolina, United States |
|
|
|
| Aarhus University – Aarhus C, Denmark |
|
|
|
| The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
|